TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39036300
Drug: Aspirin (control)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (control)
Study: 34406364
Drug: Bimekizumab (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab (640 mg at week 0, 320 mg every 2 weeks)
Study: 35645073
Drug: WhatsApp-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: WhatsApp-based oral health promotion programme
Study: 32030723
Drug: Microwave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwave therapy
Study: 34977534
Drug: Conventional Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Physical Therapy (PT)
Study: 34977534
Drug: Digital Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Exercise Therapy Application (DETA)
Study: 32213768
Drug: Na2FPO3/CaCO3 fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na2FPO3/CaCO3 fluoride toothpaste (1,378 µg F/g total soluble fluoride)
Study: 32213768
Drug: Aged fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged fluoride toothpaste (1,160 µg F/g total soluble fluoride)
Study: 32213768
Drug: Aged fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged fluoride toothpaste (900 µg F/g total soluble fluoride)
Study: 32213768
Drug: Aged fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged fluoride toothpaste (597 µg F/g total soluble fluoride)
Study: 33145642
Drug: Otelixizumab 27
Normalized name: Otelixizumab
DrugBank: Otelixizumab (DB05496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otelixizumab 27 mg
Study: 33662243
Drug: Animal Assisted
Normalized name: animals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal Assisted Therapy (AAT) with an emotional support canine in the child's lap
Study: 33168129
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment (HT) during the RCT study phase
Study: 33168129
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment (HT) under routine care conditions
Study: 33168129
Drug: Hospital ward
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital ward treatment
Study: 32213899
Drug: Casein hydrolysate
Normalized name: casein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein hydrolysate (5 g)
Study: 32764872
Drug: Collagenase Clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase Clostridium histolyticum (CCH) 0.58 mg
Study: 36122258
Drug: Nefopam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (20 mg over 30 minutes, continuous infusion for 24 hours)
Study: 34425501
Drug: Medical cannabis/cannabis-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical cannabis/cannabis-based medicine (MC/CBM)
Study: 32915972
Drug: 10-day decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day decitabine combined with ibrutinib (560 mg; sequentially given, starting the day after the last dose of decitabine) (n = 72)
Study: 36316826
Drug: Probiotic formulation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic formulation with 3 billion CFU (Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus rhamnosus)
Study: 32943750
Drug: Lomustine in
Normalized name: Product containing lomustine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomustine in combination with idarubicin and cytarabine
Study: 32943750
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy without lomustine
Study: 33260268
Drug: Medical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatments
Study: 33449095
Drug: Any aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any aspirin use
Study: 35604746
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (OB-bCBCT, HB-bCBCT, OB-PFE)
Study: 35778479
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy and 20 mL of coconut oil/day
Study: 36123169
Drug: COVID-19 vaccines
Normalized name: Covid-19 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccines
Study: 33376568
Drug: Delayed rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed rocuronium injections when BIS decreased to <60 after propofol administration (Group PRd)
Study: 35871088
Drug: Videoconferencing delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconferencing delivered cognitive behavior therapy (VCBT) weekly over a 10-week period
Study: 33339304
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (600 IU daily)
Study: 34715650
Drug: (−)-OSU6162 30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: (−)-OSU6162 30-60 mg/day for 12 weeks
Study: 34715650
Drug: (−)-OSU6162 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: (−)-OSU6162 with concomitant antidepressants
Study: 34715650
Drug: (−)-OSU6162 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: (−)-OSU6162 with beta- or calcium-channel blockers
Study: 34494112
Drug: Plant-based diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-based diet plus eggs (2 eggs daily)
Study: 33148972
Drug: β-alanine (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-alanine (6.4 g·d‐1 for 8 wk)
Study: 32600858
Drug: Partially hydrolysed
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolysed formula (pHF) with reduced lactose content and Lactobacillus reuteri DSM 17938 (L. reuteri)
Study: 35895362
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose azithromycin
Study: 35895362
Drug: 7-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day course of amoxicillin
Study: 32133778
Drug: Triprolidine 5
Normalized name: acetaminophen/pseudoephedrine/triprolidine 500 mg-30 mg-1.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine 5 mg
Study: 33752431
Drug: IV catheter
Normalized name: IV Catheter Plug
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV catheter with PosiFlow regulator and infusion clip
Study: 33752431
Drug: IV catheter
Normalized name: IV Catheter Plug
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV catheter with infusion clip
Study: 35511285
Drug: Ash‐Kardeh (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ash‐Kardeh (250 g daily for 6 weeks)
Study: 35151397
Drug: Casirivimab 4
Normalized name: REGEN-COV, 8-cartons (casirivimab 4, imdevimab 4) (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casirivimab 4 g and imdevimab 4 g administered together in a single intravenous infusion plus usual care
Study: 33761625
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin for 3 months
Study: 32448089
Drug: bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: bridging therapy (intravenous recombinant tissue-type plasminogen activator)
Study: 35368914
Drug: Human adipose
Normalized name: HUMAN ADIPOSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human adipose derived mesenchymal stem cells treatment for each 10 cm² of wound
Study: 32372176
Drug: Subcutaneous testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous testosterone pellet
Study: 32372176
Drug: Topical testosterone
Normalized name: testosterone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical testosterone gel
Study: 32998837
Drug: 2-week online
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week online oral anticoagulant counseling training
Study: 32568367
Drug: Placebo (diluent,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (diluent, daily for 12 months)
Study: 34001750
Drug: Single-dose (SGD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (SGD) containers
Study: 33831950
Drug: Continuous energy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous energy restriction (CER) - daily, 1500 kcal (6000 kJ)
Study: 37951954
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg)
Study: 32578850
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg once daily for 12 months
Study: 34800700
Drug: Immunotherapy (durvalumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (durvalumab plus tremelimumab)
Study: 34800700
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus immunotherapy (durvalumab plus tremelimumab)
Study: 33314886
Drug: Carbohydrate-protein supplement
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-protein supplement (2:2 ratio)
Study: 33314886
Drug: Carbohydrate-protein supplement
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-protein supplement (3:1 ratio)
Study: 34992867
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin chemotherapy (40 mg/m2/cycle, 5 cycles)
Study: 32534369
Drug: Hydroxychloroquine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine and azithromycin (first-choice treatment)
Study: 32750502
Drug: Upfront combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront combination therapy with fluoropyrimidine (FP), irinotecan (Iri), and bevacizumab (Bev)
Study: 32750502
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with FP and Bev followed by escalation to Iri, FP, and Bev
Study: 35653145
Drug: Abemaciclib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib (150 mg, twice daily) plus endocrine therapy (ET) for 2 years
Study: 32554173
Drug: Web-version of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-version of Prolonged Exposure (Web-PE) therapy
Study: 34992553
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy conducted by trained music therapists
Study: 34992553
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy and Music listening
Study: 36473717
Drug: Lavandula essential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavandula essential oil (LEO) - 5 drops of 20% LEO inhaled for three consecutive days, intervention performed every 24 hours.
Study: 36473717
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 5 drops of distilled water inhaled for three consecutive days, intervention performed every 24 hours.
Study: 35633027
Drug: Levetiracetam 1000
Normalized name: levetiracetam 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 1000 mg bid (starting dose 500 mg) for 12 weeks
Study: 35351020
Drug: Umbilical cord
Normalized name: Sus Scrofa Umbilical Cord
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical cord blood mononuclear cells (UCB-MNCs) administered via intrathecal route (5 × 10^6 /kg)
Study: 34016436
Drug: OnTrack application
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnTrack application for medication management
Study: 34016436
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication management
Study: 36116392
Drug: Aspirin 80
Normalized name: aspirin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 80 mg
Study: 35152576
Drug: Acupoint thread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint thread embedding therapy with PGLA thread applied to acupoints (Tianshu, Zhongwan, Ganshu, Shuidao) once every 2 weeks for 12 weeks.
Study: 32271377
Drug: Durvalumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (20 mg/kg every 4 weeks)
Study: 32271377
Drug: Durvalumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab plus tremelimumab (20 mg/kg durvalumab + 1 mg/kg tremelimumab every 4 weeks, up to 4 doses)
Study: 32770384
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (GnRHant) with estradiol add‐back
Study: 616484288
Drug: 2nd line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2nd line treatments (combining or updosing AHs)
Study: 33258890
Drug: THC-dominant cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC-dominant cannabis (13.75 mg)
Study: 33258890
Drug: THC/CBD-equivalent cannabis
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC/CBD-equivalent cannabis (13.75 mg)
Study: 33258890
Drug: CBD-dominant cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD-dominant cannabis (13.75 mg)
Study: 32804837
Drug: Allicin-containing quadruple
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allicin-containing quadruple therapy (IDFA)
Study: 32804837
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy (IDFB)
Study: 33468340
Drug: Gel pad
Normalized name: Zenphor Gel Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel pad
Study: 33167952
Drug: Narrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative medicine training
Study: 36155119
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (500 mg/day for 90 days)
Study: 33285347
Drug: Evidence-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based therapy
Study: 34539185
Drug: Colchicine and
Normalized name: colchicine and probenecid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine and Standard treatment
Study: 34296544
Drug: GEMOX-T (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX-T (gemcitabine 1000 mg/m² and oxaliplatin 50 mg/m² on day 1 and day 8 plus erlotinib 100 mg daily for 3 weeks)
Study: 34296544
Drug: GT (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT (gemcitabine 1000 mg/m² on day 1 and day 8 plus erlotinib 100 mg daily for 3 weeks)
Study: 35881893
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil (0.5‐2 mg/kg/6 hours)
Study: 34337072
Drug: Insulin titration
Normalized name: INSULIN TITRATION ORAL INHL KIT 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin titration goal of FBG≤5.6 mmol/L
Study: 34337072
Drug: Insulin titration
Normalized name: INSULIN TITRATION ORAL INHL KIT 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin titration goal of FBG≤7.0 mmol/L
Study: 34907633
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for COVID-19
Study: 37952928
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A supplementation
Study: 35398532
Drug: Fidaxomicin (FDX)
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fidaxomicin (FDX) 200 mg twice daily for 10 days
Study: 35398532
Drug: Vancomycin (VAN)
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin (VAN) 125 mg four times daily for 10 days followed by a 3-week vancomycin taper and pulse (VAN-T/P) regimen
Study: 33975993
Drug: Denosumab-biosimilar (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab-biosimilar (60 mg subcutaneous every 6 months for 1 year)
Study: 32533723
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) 1 mg/kg
Study: 32533723
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) 0.3 mg/kg
Study: 34167868
Drug: Alendronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (35 mg) administered orally every week for 8 weeks
Study: 34167868
Drug: Alendronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (35 mg)
Study: 33482894
Drug: Oral melatonin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin, 3 mg/kg/day for 15 days
Study: 32369655
Drug: 1% Acetyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Acetyl zingerone (AZ) applied twice daily for 8 weeks
Study: 32369655
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle base cream) applied twice daily for 8 weeks
Study: 34752019
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine (10 μg, 2 doses, administered 21 days apart)
Study: 32747975
Drug: TAS‐303 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS‐303 18 mg
Study: 35460165
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of trazpiroben 25 mg (treatment A)
Study: 35726033
Drug: 800 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU/day of oral vitamin D3
Study: 35726033
Drug: 400 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU/day of oral vitamin D3
Study: 33302976
Drug: Nebulised surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised surfactant (Bovactant, Alveofact®) administered at varying doses (10 vials at 0, 8, and 24 hours or 30 vials at 24 hours)
Study: 33683076
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (COCs) and laser hair removal
Study: 33683076
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and laser hair removal
Study: 33310565
Drug: Bilateral cochlear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral cochlear implants (CIs) on
Study: 33310565
Drug: Bilateral cochlear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral cochlear implants (CIs) off
Study: 32432695
Drug: Wait list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait list control (treatment as usual for 8 weeks)
Study: 32623510
Drug: Bencycloquidium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencycloquidium bromide nasal spray (BCQB)
Study: 33359277
Drug: Overall population
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall population with RAS inhibitors
Study: 32729763
Drug: Moderate exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate exercise after α/β adrenergic blocker (labetalol, 100 mg orally)
Study: 32729763
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion for 20 minutes
Study: 33259643
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein pre-meal (20 g)
Study: 38336815
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository
Study: 33657970
Drug: Neurological music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurological music therapy (2 times/week, 60 min/session for 3 months)
Study: 32535812
Drug: Selatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selatinib (500 mg)
Study: 32453393
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (2000 IU daily for 6 months)
Study: 32453393
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1000 mg daily for 6 months)
Study: 32388522
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (placebo)
Study: 33484479
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic therapy (Lactobacillus fermentum CECT5716)
Study: 34602460
Drug: sl‐wIRAR treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sl‐wIRAR treatment (2 treatments/day for 30 min each for 6 days)
Study: 32224045
Drug: Disease flare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease flare during tapering of DMARDs
Study: 34844641
Drug: Magnesium supplements
Normalized name: Magnesium supplements, alimentary tract and metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplements
Study: 33150703
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy and risperidone
Study: 36501070
Drug: Betaine anhydrous
Normalized name: Betaine Anhydrous
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine anhydrous (BET) 6 g/day for 14 days
Study: 32130742
Drug: Treatment 1
Normalized name: CVS Acne Treatment 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 1
Study: 32749941
Drug: Combined adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined adjuvant chemotherapy and radiotherapy (CTRT)
Study: 35291433
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg)
Study: 32985001
Drug: Fermented barley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented barley - wheat flour compound noodle (FBWN)
Study: 32869580
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with Hydroprednisone (2 mg•kg‐1•d‐1)
Study: 32035708
Drug: Tetravalent Inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent Inactivated Influenza Vaccine (TIV)
Study: 32653075
Drug: High-dose MF–IND
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MF–IND (320 μg, 150 μg) once daily
Study: 34650220
Drug: Prediction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction of month 7-8 post-treatment retinal sensitivity from baseline SD-OCT data
Study: 32779505
Drug: Epeleuton 2
Normalized name: Epeleuton
DrugBank: Epeleuton (DB18100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epeleuton 2 g/day